Parathyroid diseases and animal models
- PMID: 22754549
- PMCID: PMC3384071
- DOI: 10.3389/fendo.2012.00078
Parathyroid diseases and animal models
Abstract
CIRCULATING CALCIUM AND PHOSPHATE ARE TIGHTLY REGULATED BY THREE HORMONES: the active form of vitamin D (1,25-dihydroxyvitamin D), fibroblast growth factor (FGF)-23, and parathyroid hormone (PTH). PTH acts to stimulate a rapid increment in serum calcium and has a crucial role in calcium homeostasis. Major target organs of PTH are kidney and bone. The oversecretion of the hormone results in hypercalcemia, caused by increased intestinal calcium absorption, reduced renal calcium clearance, and mobilization of calcium from bone in primary hyperparathyroidism. In chronic kidney disease, secondary hyperparathyroidism of uremia is observed in its early stages, and this finally develops into the autonomous secretion of PTH during maintenance hemodialysis. Receptors in parathyroid cells, such as the calcium-sensing receptor, vitamin D receptor, and FGF receptor (FGFR)-Klotho complex have crucial roles in the regulation of PTH secretion. Genes such as Cyclin D1, RET, MEN1, HRPT2, and CDKN1B have been identified in parathyroid diseases. Genetically engineered animals with these receptors and the associated genes have provided us with valuable information on the patho-physiology of parathyroid diseases. The application of these animal models is significant for the development of new therapies.
Keywords: CKD; CaR; FGF-23; Klotho; PTH; calcitriol; cinacalcet; hyperparathyroidism.
Figures


Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.J Ren Nutr. 2006 Jul;16(3):253-8. doi: 10.1053/j.jrn.2006.04.010. J Ren Nutr. 2006. PMID: 16825031 Review.
-
Hyperparathyroidism in Chronic Kidney Disease.2025 Feb 14. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2025 Feb 14. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905209 Free Books & Documents. Review.
-
Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.Eur J Endocrinol. 2005 Oct;153(4):587-94. doi: 10.1530/eje.1.02007. Eur J Endocrinol. 2005. PMID: 16189180
-
Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.Ther Apher Dial. 2007 Oct;11 Suppl 1:S32-7. doi: 10.1111/j.1744-9987.2007.00519.x. Ther Apher Dial. 2007. PMID: 17976083 Review.
References
-
- Carpten J. D., Robbins C. M., Villablanca A., Forsberg L., Presciuttini S., Bailey-Wilson J., Simonds W. F., Gillanders E. M., Kennedy A. M., Chen J. D., Agarwal S. K., Sood R., Jones M. P., Moses T. Y., Haven C., Petillo D., Leotlela P. D., Harding B., Cameron D., Pannett A. A., Hoog A., Heath H., III, James-Newton L. A., Robinson B., Zarbo R. J., Cavaco B. M., Wassif W., Perrier N. D., Rosen I. B., Kristoffersson U., Turnpenny P. D., Farnebo L. O., Besser G. M., Jackson C. E., Morreau H., Trent J. M., Thakker R. V., Marx S. J., Teh B. T., Larsson C., Hobbs M. R. (2002). HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32, 676–68010.1038/ng1048 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous